FDA Designates Review Completion Date for Ovarian Cancer Drug Relacorilant

The U.S. Food and Drug Administration has accepted Corcept Therapeutics' New Drug Application for relacorilant, a potential treatment for platinum-resistant ovarian cancer. The agency has set a Prescription Drug User Fee Act target action date for July 11, 2026. This marks a significant step in the regulatory process for the drug's potential market approval.